Biopharmaceutical company Trevena, Inc. (TRVN) announced Monday that the Imperial College London (ICL) has initiated a proof-of-concept study for TRV027 in COVID-19 patients. The company expects to report topline data in the first quarter of fiscal 2021.
from RTT - Biotech https://ift.tt/3aP0ROa
via IFTTT
No comments:
Post a Comment